Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

On location

Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML

In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen...
On location

Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML

Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from Memorial Sloan Kettering Cancer Center identified 14 distinct molecular...
On location

Olutasidenib Shows Promise for Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia

Olutasidenib, an investigational IDH1 inhibitor selective for mutant IDH1, was well tolerated and associated with durable complete remissions (CRs) in patients with high-risk, relapsed/refractory...

FDA Clears IND Application for Gamma Delta T-Cell Therapy

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for GDX012 to be examined as a therapy for...
On location

How Do Perceptions about Side Effects Influence Treatment Decisions and Outcomes in AML?

Patients’ negative perception of the side effects of intensive chemotherapy (IC) for acute myeloid leukemia (AML) may be associated with undertreatment and worse outcomes,...
On location

First-in-Human Study Finds FF-10101-01 Has Clinical Activity in Relapsed/Refractory FLT3-Mutated AML

For patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia (AML), treatment with the selective and irreversible FLT3 inhibitor FF-10101-01 had promising clinical activity....
On location

Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile...

Comparing Real-World Versus Clinical Trial Outcomes for Acute Promyelocytic Leukemia

A recent study published in Leukemia & Lymphoma examined one-month mortality and overall survival (OS) data of patients diagnosed with acute promyelocytic leukemia (APL)...

Can Caloric Restriction Improve Chemotherapy Response in Overweight Patients With ALL?

Previous reports have found that patients who are overweight or obese during B-cell acute lymphocytic leukemia (B-ALL) induction therapy are at a higher risk...

Next-Generation Karyotyping Outperforms Conventional Cytogenetics for Prognostication of AML

Compared with conventional cytogenetic analysis (CCA), next generation sequencing (NGS)–based karyotyping offered greater insight into the prognosis of patients with intensively treated acute myeloid...